RIVM writes Novel Tobacco Products paper for WHO The World Health Organization (WHO) Tobacco Free Initiative (TFI) has just published a Report of the WHO Study Group on Tobacco Product Regulation (TobReg).
Risks of chemical substances to human health and the environment RIVM is developing methods to identify new and emerging risks of chemical substances to workers, consumers and the environment.
Harmful substances in e-cigarettes assessed While e-cigarettes are less harmful to health than tobacco cigarettes, the vapour from an e-cigarette contains substances and chemical impurities in concentrations that could be detrimental to heal
RIVM and Olive Foundation open trading to mark the European Cervical Cancer Prevention Week January 20th, the Olive Foundation and RIVM opened AEX trading day in Amsterdam on the occasion of the 9th European Cervical Cancer Prevention Week.
The National Immunisation Programme in the Netherlands 2013 - 2014 Every year, RIVM provides an overview of surveillance and developments in the National Immunisation Programme (NIP).
RIVM presents four scenarios on future public health at European Health Forum Gastein On the first day of the 17th European Health Forum Gastein (EHFG), the Dutch National Institute for Public Health and the Environment (RIVM) organises a workshop on ‘Our health in 2040’.
RIVM forecasting study: a healthier Netherlands with more people living with a chronic disease Dutch people are reaching an increasingly advanced age: in 2030, the life expectancy of men will be 82 years, and of women, 85.
Increasing number of girls immunised against HPV In 2014 the number of girls who were immunised against the human papilloma virus (HPV) rose. This virus can cause cervical cancer later in life.
RIVM investigates dangers of e-cigarette At the request of State Secretary Martin van Rijn (VWS), RIVM is carrying out an investigation into the safety of e-cigarettes.
The National Immunisation Programme in the Netherlands: Developments in 2013 Annually RIVM provides an overview of key events and developments in the National Immunisation Programme (NIP).